Pep-1 (uncapped)

O=C(N1[C@@H](CCC1)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@H](C(O)=O)C(C)C)=O)=O)=O)=O)=O)=O)[C@H](CCC(N)=O)NC([C@H](CO)NC([C@H](CC2=CNC3=CC=CC=C23)NC([C@H](CCC(O)=O)NC([C@H]([C@H](O)C)NC([C@H](CC4=CNC5=CC=CC=C45)NC([C@@H](NC([C@H]([C@H](O)C)NC([C@H](CCC(O)=O)NC([C@@H](NC([C@@H](NC([C@H]([C@H](O)C)NC([C@H](CCC(O)=O)NC([C@@H](N)CCCCN)=O)=O)=O)CC6=CNC7=CC=CC=C67)=O)CC8=CNC9=CC=CC=C89)=O)=O)=O)CC%10=CNC%11=CC=CC=C%10%11)=O)=O)=O)=O)=O)=O

[1]Almarwani B, et al. Vesicles mimicking normal and cancer cell membranes exhibit differential responses to the cell-penetrating peptide Pep-1. Biochim Biophys Acta Biomembr. 2018 Jun;1860 (6) :1394-1402.|[2]Wang B, et al. Nanoparticles functionalized with Pep-1 as potential glioma targeting delivery system via interleukin 13 receptor α2-mediated endocytosis. Biomaterials. 2014 Jul;35 (22) :5897-907.